menu
    • menu

    Company profile for Yuhan Corporation

    NEW Drugs in Dev: 55
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    EXCIPIENTS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    After returning from the USA in 1925, Dr. Ilhan New witnessed the hardship in his country under Japanese imperialism. He founded the Yuhan corporation in 1926 with the belief that only healthy people could reclaim their sovereignty and he sought to solve widespread public health problems. Over 80 years, the founding creed to make the best medicines and contribute to public health has been succeeded by us through our intense re...
    After returning from the USA in 1925, Dr. Ilhan New witnessed the hardship in his country under Japanese imperialism. He founded the Yuhan corporation in 1926 with the belief that only healthy people could reclaim their sovereignty and he sought to solve widespread public health problems. Over 80 years, the founding creed to make the best medicines and contribute to public health has been succeeded by us through our intense research and development activities and successful collaboration with multinational pharmaceutical companies. As a result, Yuhan is one of the most respected companies in Korea for 20 consecutive years, according to the annual Korean Management Association Consulting (KMAC) survey. Yuhan has been playing active role in global citizenship since its foundation in 1926. Even before global citizenship was conceptualized, Dr. New believed that was the duty and responsibility of business to develop itself for the prosperity of all society, and his own personal commitment to this was the donation of all of his personal property throughout his life up until his death. Yuhan is continuously making its social contribution by establishing a system where part of the company’s profits is returned to society. This endeavor has been domestically and internationally recognized through various organizations and publications. Yuhan has always emphasized research and development as its top corporate priority. The company approaches R&D through innovative, nimble and translational methodologies. This three-fold dynamic allows Yuhan to continue its over-arching commitment to enhancing quality of life. True to the company’s founding mission, Yuhan focuses its R&D efforts on developing the kinds of products people need most. By developing therapies for treating inflammatory, autoimmune, oncologic and metabolic diseases, Yuhan has significantly advanced the science and understanding of these prevalent disease processes. This rich body of knowledge and wealth of experience positions Yuhan on the cutting edge for developing unique, innovative, finished products and to partnering successfully with other developers. Yuhan has been playing active role in global citizenship since its foundation in 1926. Even before global citizenship was conceptualized, Dr. New believed that was the duty and responsibility of business to develop itself for the prosperity of all society, and his own personal commitment to this was the donation of all of his personal property throughout his life up until his death. Yuhan is continuously making its social contribution by establishing a system where part of the company’s profits is returned to society. This endeavor has been domestically and internationally recognized through various organizations and publications. The R&D Priority Yuhan has always emphasized research and development as its top corporate priority. The company approaches R&D through innovative, nimble and translational methodologies. This three-fold dynamic allows Yuhan to continue its over-arching commitment to enhancing quality of life. True to the company’s founding mission, Yuhan focuses its R&D efforts on developing the kinds of products people need most. By developing therapies for treating inflammatory, autoimmune, oncologic and metabolic diseases, Yuhan has significantly advanced the science and understanding of these prevalent disease processes. This rich body of knowledge and wealth of experience positions Yuhan on the cutting edge for developing unique, innovative, finished products and to partnering successfully with other developers. Yuhan: A Global Best Partner Equipped with state-of-the-art research capabilities and manufacturing facilities compliant with the United States Food and Drug Administration (FDA) current Good Manufacturing Practices (cGMP) regulations, Yuhan is growing into a global pharmaceutical company that offers one-stop custom synthesis services from R&D to commercial production of active pharmaceutical products (APIs) and intermediates. Yuhan has undergone successful audits by many international regulatory agencies such as the FDA, the European Medicines Agency and the European Directorate for the Quality of Medicines (EMEA/EDQM), Australia’s Therapeutic Goods Amdinistration (TGA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). Yuhan has successfully provided high-quality APIs and intermediates for the following disease treatments: antivirals (HCV and HIV), antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds for international markets. Yuhan continues to expand its overseas markets by supplying finished products. The process began in 2010 with the out-licensing to China of Yuhan’s Revanex, the world’s first acid pump antagonist (APA). Revanex is now supplied world-wide to India, Southeast Asia, South America and the Middle East, improving the health and quality of life for individuals suffering from peptic ulcers and gastritis-related mucosal injury.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Yuhan Corporationkorearepublicofnew Flag
    Country
    Country
    South Korea
    Address
    Address
    74, Noryangjin-ro, Daebang-dong, Dongjak-gu, SEOUL
    Telephone
    Telephone
    +82-2-828-0181
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://eng.yuhan.co.kr/Main/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CJ Biomaterials, Yuhan-Kimberly Launch First PHA Paper Towel
    CJ Biomaterials, Yuhan-Kimberly Launch First PHA Paper Towel

    07 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/07/3290062/0/en/cj-biomaterials-and-yuhan-kimberly-launch-world-s-first-reusable-nonwoven-paper-towel-made-with-amorphous-pha.html

    GLOBENEWSWIRE
    07 May 2026
    Share Share
    Yuhan makes $325M cancer bet to challenge Boehringer, Takeda
    Yuhan makes $325M cancer bet to challenge Boehringer, Takeda

    31 May 2023

    // Nick Paul Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/yuhan-makes-325m-cancer-bet-challenge-boehringer-takeda

    Nick Paul Taylor FIERCE BIOTECH
    31 May 2023
    Share Share
    Hanmi, LG Chem, Yuhan race to develop new obesity drug
    Hanmi, LG Chem, Yuhan race to develop new obesity drug

    23 May 2022

    // Kim Chan-hyuk KOREABIOMED

    http://www.koreabiomed.com/news/articleView.html?idxno=13737

    Kim Chan-hyuk KOREABIOMED
    23 May 2022
    Share Share
    Yuhan gets $9.97M milestone payment from Boehringer Ingelheim for NASH therapy
    Yuhan gets $9.97M milestone payment from Boehringer Ingelheim for NASH therapy

    17 Nov 2021

    // Shim Hyun-tai KOREABIOMED

    https://www.koreabiomed.com/news/articleView.html?idxno=12577

    Shim Hyun-tai KOREABIOMED
    17 Nov 2021
    Share Share
    Yuhan gets $65m from Janssen for lazertinib milestone achievement
    Yuhan gets $65m from Janssen for lazertinib milestone achievement

    23 Nov 2020

    // KOREAHERALD

    http://www.koreaherald.com/view.php?ud=20201123000807#:~:text=Yuhan%20gets%20%2465m%20from%20Janssen%20for%20lazertinib%20milestone%20achievement&text=Yuhan%20Corp.%20made%20a%20regulatory,milestone%20payment%20from%20Janssen%20Biotech.

    KOREAHERALD
    23 Nov 2020
    Share Share
    Yuhan in-licenses GI Innovation’s allergy treatment pipeline for $1.2b
    Yuhan in-licenses GI Innovation’s allergy treatment pipeline for $1.2b

    01 Jul 2020

    // By Lim Jeong-yeo KOREAHERALD

    http://www.koreaherald.com/view.php?ud=20200701000846

    By Lim Jeong-yeo KOREAHERALD
    01 Jul 2020
    Share Share

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Yuhan Corporation and get a quotation

    Yuhan Corporation is a supplier offers 25 products (APIs, Excipients or Intermediates).

    Find Piperacillin Sodium bulk with DMF, CEP offered by Yuhan Corporation

    Find Levofloxacin bulk with JDMF offered by Yuhan Corporation

    Find Ribavirin bulk with DMF offered by Yuhan Corporation

    Find Cilostazol bulk with JDMF offered by Yuhan Corporation

    Find Ketoprofen bulk with JDMF offered by Yuhan Corporation

    Find Rosuvastatin Calcium bulk with JDMF offered by Yuhan Corporation

    Find Voglibose bulk with JDMF offered by Yuhan Corporation

    Find Cefaclor bulk offered by Yuhan Corporation

    Find Zidovudine bulk offered by Yuhan Corporation

    Find FACILITY AND OPERATING PROCEDURES IN ANSANSHI, KYONGGI-DO, SOUTH KOREA bulk offered by Yuhan Corporation

    Find Acoramidis Hydrochloride bulk offered by Yuhan Corporation

    Find Atorvastatin bulk offered by Yuhan Corporation

    Find Cobicistat bulk offered by Yuhan Corporation

    Find Elvitegravir bulk offered by Yuhan Corporation

    Find Emtricitabine bulk offered by Yuhan Corporation

    Find Ezetimibe bulk offered by Yuhan Corporation

    Find Lazertinib bulk offered by Yuhan Corporation

    Find Ledipasvir bulk offered by Yuhan Corporation

    Find Lenacapavir bulk offered by Yuhan Corporation

    Find Revaprazan bulk offered by Yuhan Corporation

    Find Sarpogrelate Hydrochloride bulk offered by Yuhan Corporation

    Find Tazobactam Sodium bulk offered by Yuhan Corporation

    Find Telmisartan bulk offered by Yuhan Corporation

    Find Velpatasvir bulk offered by Yuhan Corporation

    Find Voxilaprevir bulk offered by Yuhan Corporation

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search